Concepedia

Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma

Evangelos Terpos, John Palermos, Konstantinos Tsionos, Konstantinos Anargyrou, Nora Viniou, Pantelis Papassavas, John Meletis, Xenophon Yataganas

European Journal Of Haematology · 2000 · 71 citations · 17 references

DOI

Abstract

These results suggest that pamidronate may have a synergistic action with chemotherapy in decreasing osteoclastic activity, in reducing markers of myeloma activity and myeloma related pain and in improving the quality of life in patients with MM.

References

17

A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine

Dennis A. Hanson, Mary Ann Weis, Anne‐Marie Bollen et al. · Journal of Bone and Mineral Research · 1992 · 669 citations

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

James R. Berenson, Alan Lichtenstein, Lisa A. Porter et al. · Journal of Clinical Oncology · 1998 · 652 citations

Interleukin-6 in human multiple myeloma

Bernard Klein, XG Zhang, Lu Zy et al. · Blood · 1995 · 533 citations · Full text

, , +7

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma

R Lahtinen, Markku Laakso, I. P. Palva et al. · The Lancet · 1992 · 389 citations

, , +5

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

McCloskey, MacLennan, Mark T. Drayson et al. · British Journal of Haematology · 1998 · 318 citations